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The 28 amino acid vasoactive intestinal peptide (VIP) and 38 amino
acid pituitary adenylate cyclase-activating polypeptide (PACAP) are
structurally related neuropeptides that have several overlapping and
distinct functions in the central nervous system (CNS) and periph-
ery (1–5). Three genes have been cloned that encode distinct
VIP⁄PACAP receptor proteins belonging to the class II secretin
receptor G protein-coupled receptor (GPCR) family (6–8). Two are
receptors at which VIP and PACAP are equipotent and have been
designated the VPAC1 and the VPAC2 receptors. The third receptor,
at which PACAP ‡100-fold more potent than VIP, has been desig-
nated the PAC1 receptor (9). Further diversity in VPAC⁄PAC1 recep-
tor isoforms is generated through alternative splicing of their
respective genes, including several N-terminal and intracellular loop
3 splice variants of the PAC1 receptor (10–14), and the recently
identiﬁed D exon 12 variant of the VPAC2 receptor (15). Similar to
other members of the class II secretin receptor GPCR family, the
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The VPAC2 receptor is a seven transmembrane spanning G protein-coupled receptor for two
neuropeptides, vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating poly-
peptide (PACAP). It has a distinct tissue-speciﬁc, developmental and inducible expression that
underlies an important neuroendocrine role. Here, we report the characterisation of the gene
that encodes the mouse VPAC2 receptor (Vipr2), localisation of the transcriptional start site and
functional analysis of the promoter region. The Vipr2 gene contains 12 introns within its pro-
tein-coding region and spans 68.6 kb. Comparison of the 5¢ untranslated region sequences for
cloned 5¢-RACE products ampliﬁed from different tissues showed they all were contained within
the same exon, with the longest extending 111 bp upstream of the ATG start site. Functional
analysis of the 3.2-kb 5¢-ﬂanking region using sequentially deleted sequences cloned into a lu-
ciferase gene reporter vector revealed that this region is active as a promoter in mouse AtT20
D16:16 and rat GH4C1 cell lines. The core promoter is located within a 180-bp GC-rich region
proximal to the ATG start codon and contains potential binding sites for Sp1 and AP2, but no
TATA-box. Further upstream, in two out of three mice strains examined, we have discovered a
496-bp polymorphic DNA sequence that bears a signiﬁcant identity to mouse LINE-1 DNA. Com-
parison of the promoter activity between luciferase reporter gene constructs derived from the
BALB⁄c (which contains this sequence) and C57BL⁄6J (which lacks this sequence) Vipr2 promo-
ter regions has shown three-fold difference in luciferase gene activity when expressed in mouse
AtT20 D16:16 and aT3-1 cells, but not when expressed in the rat GH4C1 cells or in COS 7 cells.
Our results suggest that the mouse Vipr2 gene may be differentially active in different mouse
strains, depending on the presence of this LINE-1-like sequence in the promoter region.
Key words: vasoactive intestinal peptide (VIP), pituitary adenylate cyclase activating polypeptide
(PACAP), G protein-coupled receptor, gene, LINE-1.
doi: 10.1111/j.1365-2826.2006.01498.x
Journal of Neuroendocrinology 19, 14–25
ª 2006 The Authors. Journal Compilation ª 2006 Blackwell Publishing Ltd
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.VPAC⁄PAC1 receptors couple to adenylate cyclase activation and
are capable also of coupling to additional second messenger path-
ways through distinct interactions with different heterotrimeric and
small G proteins (16). The diversity in receptor isoforms generated
by alternative splicing is reﬂected by altered ligand activation and
G protein coupling for the VPAC⁄PAC1 receptors. For example, there
are notable differences in the activation of certain N-terminal
domain PAC1 receptor splice variants by VIP (14) and for the PAC1-
hop-1 but not the PAC1-null intracellular loop 3 isoforms; coupling to
phospholipase D activation involves an additional ADP ribosylation
factor-dependent pathway (17, 18). In addition, the VPAC2 receptor
D exon 12 variant does not couple to adenylate cyclase activation
(15). These differences may underlie the various actions of VIP and
PACAP in different tissues and cell-types.
The distinct expression proﬁle of the VPAC2 receptor in the CNS
and also in several endocrine cell types and tissues (7, 19–23) has
prompted the suggestion that the VPAC2 receptor may be respon-
sible for mediating the neuroendocrine effects of VIP (19). In the
pituitary, VPAC2 receptor expression levels are up-regulated during
pregnancy (19), where one of its roles may be to mediate the
potent prolactin-releasing action of VIP. The VPAC2 receptor also is
expressed in several pituitary-derived clonal cell lines including rat
somatomammotroph GH3 and GH4C1 cells, mouse adrenocortico-
troph AtT20 and gonadotroph aT3-1 cells (21, 24, 25) suggesting
that, in addition to its role in mediating VIP and PACAP regulation
of the synthesis and release of different pituitary hormones, it may
have a role also in the development of pituitary cell lineages. In
support of this, expression is detected quite early in development,
and transcripts encoding VPAC2 receptors are expressed in mouse
embryonic stem cells (26, 27) and mouse embryonic brain tissue as
early as E9.5 (28). In the adult brain, mRNA encoding the VPAC2
receptor is present at relatively high levels in the suprachiasmatic
nucleus, thalamus, hippocampus, olfactory bulb, and several of the
hypothalamic nuclei, in agreement with the mapping of VPAC2
receptor binding sites using a receptor-speciﬁc ligand (29). The
VPAC1 receptor is constitutively expressed in a number of different
immune cell types whereas expression of the VPAC2 receptor is
induced in certain monocytes and lymphocytes only after activation
(30–32), suggesting that the VPAC1 and VPAC2 receptors have dif-
ferent roles in mediating the anti-inﬂammatory and immunomodu-
latory actions of VIP and PACAP (32). Expression of the VPAC2
receptor is induced also in spinal glial cells following a chronic con-
strictive nerve injury (33) where it participates in sensory sensitisa-
tion involving p38 MAP kinase activation (34).
Very little is known about the regulatory elements involved in
the tissue-speciﬁc, inducible, and developmentally regulated
expression of the gene encoding the VPAC2 receptor. Previously,
we reported the characterisation of the human VPAC2 receptor
gene and identiﬁcation of a putative proximal promoter region
(35). In the present study, we have characterised the mouse
VPAC2 receptor gene, Vipr2. The transcriptional start sites were
determined by 5¢-RACE polymerase chain reaction (PCR) analysis
utilising several anchored cDNA libraries derived from different
mouse tissues and embryonic stages. In addition, the promoter
activity and core promoter region within 3.2 kb of 5¢-ﬂanking
sequence were characterised using luciferase reporter gene con-
structs transiently expressed in different pituitary cell lines. Recent
research has suggested that polymorphisms of the human VIPR2
gene promoter may play a role in autism by altering transcrip-
tional regulation and the level of protein expression (36). Here,
we have identiﬁed a polymorphic LINE-1 (L1)-like sequence that is
present in the Vipr2 promoter region in 129 and Balb⁄c but not
in C57Bl⁄6J and show that this sequence confers increased
expression levels of a luciferase reporter gene.
Materials and methods
Materials
Tissue culture media and Lipofectamine 2000 were obtained from Invitrogen
(Paisley, UK); Primocin from Autogen Bioclear UK Ltd (Calne, UK); Genejuice
from Novagen, Merck Biosciences Ltd (Nottingham, UK); standard laboratory
chemicals of Analar grade were obtained from Sigma or BDH Chemicals Ltd
(Poole, UK); oligonucleotide primers were obtained from Oswel DNA Service
(Southampton, UK) and Life Technologies (Paisley, UK).
Anchored 5¢-RACE (rapid ampliﬁcation of cDNA ends) for
the mouse VPAC2 receptor cDNA
Total RNA was isolated from the mouse adrenocorticotroph AtT20 D16:16
cell line using Catriomox-14 surfactant reagent (VH BIO Ltd, Newcastle-
upon-Tyne, UK). Poly A+ RNA was isolated from AtT20 total RNA with the
Qiagen Oligotex kit and an anchored cDNA library synthesised from 1 lgo f
poly A+ RNA using the Clontech Marathon cDNA Ampliﬁcation kit (BD Bio-
sciences, Oxford, UK). The 5¢ end of the mouse VPAC2 receptor was ampliﬁed
using the Clontech anchor primer AP1, and the VPAC2 receptor speciﬁc pri-
mer exon4.rp (5¢-ATGTCTCTGACCATCCATCGC-3¢), in a 35-cycle touchdown
PCR reaction with Advantage KlenTaq Polymerase Mix (BD Biosciences)
according to the manufacturer’s guidelines. Ampliﬁcation products were
checked by gel electrophoresis and Southern blotting. The ﬁrst round ampli-
ﬁcation reaction then was diluted 1 : 100 ll with sterile H2O, and a second
round of PCR was performed under the same conditions using 5 ll of dilu-
ted ﬁrst round mix together with the Clontech nested primer AP2 and the
mouse VPAC2 receptor speciﬁc primer exon1.rp (5¢-CAGCAACCAGCAGTAGCA-
GGTCAGCACCAC-3¢). Total RNA was isolated from olfactory bulb tissue from
BALB⁄c and from C57BL⁄6J mouse strains with the Wizard RNA kit (Prome-
ga, Southampton, UK). Anchored cDNA libraries were synthesised from 1 lg
total RNA using the Clontech SMART RACE cDNA ampliﬁcation kit (BD Bio-
sciences) and Superscript II (Invitrogen). The 5¢ end of the mouse VPAC2
receptor was ampliﬁed with the Clontech anchor primer 5¢UPM and the
VPAC2 receptor speciﬁc primer exon11.rp (5¢-GCCAAACAGGGGGATTAGCAG-
CAG-3¢) using the HF2 Advantage PCR kit (BD Biosciences) and the touch-
down PCR method. The ﬁnal ampliﬁcation products were size selected by
gel electrophoresis, subcloned into the pGEM-T Easy vector (Promega) and
sequenced in both directions.
Sure-RACE mouse panels (Origene Technologies Inc., Cambridge Bio-
science, Cambridge, UK) were used as described by the manufacturer but
with the Advantage-GC2 kit (BD Biosciences) and Taq DNA polymerase
(Stratagene Europe, Amsterdam, the Netherlands). For ﬁrst round ampliﬁca-
tion, the Sure-RACE anchor primer ADP1 and the VPAC2 receptor speciﬁc
primer exon5.rp (5¢-GCCCAAGGTATAAATGGCCTTC-3¢) were used in a 20-cycle
touchdown PCR reaction. The ﬁrst round ampliﬁcation reaction then was
diluted 1 : 100 ll with sterile H2O, and a second round of PCR was per-
formed under the same conditions using 5 ll of diluted ﬁrst round mix
together with the Sure-RACE nested primer ADP2 and the mouse VPAC2
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second round ampliﬁcation products were separated by agarose gel electro-
phoresis and visualised following staining with ethidium bromide with a uv
light box. Ampliﬁcation products were isolated following gel electrophoresis,
subcloned into the pCR4-TOPO vector using the TOPO TA cloning kit
(Invitrogen) and recombinant plasmids were sequenced.
Reporter plasmids used in expression studies
A genomic DNA clone (kESD1) containing the Vipr2 exon 1, intron 1 and
exon 2 along with the 5¢ ﬂanking sequence was isolated previously from
a k2001 genomic DNA library made from mouse strain 129-derived ES
cell DNA (provided by Dr A. J. H. Smith, Centre for Genome Research,
University of Edinburgh, Edinburgh, UK) and the 5.6-kb XbaI fragment
spanning this region subcloned into pGEM11z (Promega). The 3.2-kb
XbaI⁄SfoI fragment spanning the 5¢ sequence and part of exon 1 prior to
the translational start site ()3300⁄)33) was subcloned into the reporter
plasmid pGL3-Basic (Promega). Deletion mutants were created by subclon-
ing smaller fragments generated using restriction enzyme sites, including
the 2.5-kb NheI⁄SfoI( )2514⁄)33), 1.6-kb HindIII⁄SfoI( )1642⁄)33), 0.55-
kb NcoI⁄SfoI( )584⁄)33), 0.18-kb BglII⁄SfoI( )212⁄)33) and 3-kb
XbaI⁄BglII ()3300⁄)213) constructs. The 2.2-kb SfoI⁄XhoI fragment
()32⁄+2167) was also subcloned into pGL3-Basic. The C57BL⁄6J and
BALB⁄c reporter constructs were created by amplifying genomic DNA iso-
lated from each mouse strain with the oligonucleotide primer pair 15075
(5¢-GTAGCCCCTAATGGGTCGAGTGT-3¢) and 8484 (5¢-GCACCAGCAACCAG-
CAGTAG-3¢) using the GC-melt genomic PCR kit (BD Biosciences). Ampliﬁ-
cation products were gel puriﬁed, subcloned into pGEMTeasy (Promega)
and veriﬁed by sequencing. The SpeI⁄SfoI fragments from each were then
subcloned into pGL3-Basic.
Cell culture and transfection
Mouse adrenocorticotroph AtT20 D16:16 cells were maintained in Dulbecco’s
modiﬁed Eagle medium (DMEM) containing 10% fetal calf serum (FCS) and
5 lg⁄ml Primocin. Mouse gonadotroph aT3-1 cells were maintained in
DMEM supplemented with 100 lM pyruvate, 5 lg⁄ml Primocin and 10%
FCS. Rat somatomammotroph GH4C1 cells were maintained in Ham’s F10
medium supplemented with 15% horse serum, 2.5% FCS and 5 lg⁄ml Pri-
mocin. COS 7 cells were maintained in DMEM containing 10% normal calf
serum and 5 lg⁄ml Primocin. One day prior to transfection, cells were
trypsinised and 1 · 10
5 cells⁄well plated into 24-well plates. aT3-1 cells
were transfected using Lipofectamine 2000 and AtT20, GH4C1 and COS 7
cells were transfected using GeneJuice according to the manufacturer’s
guidelines. Brieﬂy, the transfection reagent to plasmid DNA was used in a
ratio of 3 : 1 and diluted in OptiMEM. Cells were cotransfected with a 3 : 1
mixture of the experimental pGL3 reporter construct and the control pRL-TK
plasmid encoding Renilla luciferase (Promega) for normalisation.
Reporter gene assays
Luciferase activity was measured with the Dual-Glo Luciferase Assay System
(Promega). Culture medium was removed from transfected cells in each well
and replaced with 75 ll of DMEM along with 75 ll of Dual-Glo Luciferase
Reagent. Samples were incubated for 10 min at room temperature, then
transferred to a white 96-well plate (Costar, Fisher Scientiﬁc, Loughborough,
UK). Fireﬂy luciferase activity was measured with a BMG Labtech LUMIstar
Galaxy Plate Reader (BMG Labtech Ltd, Aylesbury, Bucks, UK). Immediately
afterwards, 75 llo fRenilla luciferase reagent diluted in Stop-Glo buffer
was added to each well, and the plate incubated for 10 min at room
temperature before measuring Renilla luciferase activity.
Results
The mouse VPAC2 receptor is encoded by 13 exons
The organisation of the mouse Vipr2 gene was determined by align-
ment of the mouse VPAC2 receptor cDNA sequence (37) with the
Genebank deposited genomic DNA sequences of the mouse chro-
mosome 12 clone RP24-386J17 (accession number AC105950), the
C57BL⁄6J clone RP23-32J01 (accession number AC073564) and
the DNA sequence obtained for genomic clones encoding the
mouse Vipr2 previously isolated through the screening of a k2001
mouse 129 strain embryonic stem cell-derived genomic library
(Mackay, West, Lutz and Harmar, unpublished data; the ES-129
Vipr2 gene sequence has been deposited in the EMBL database
under the accession numbers AJ272314-AJ272323) The protein cod-
ing region of the mouse Vipr2 gene (Fig. 1A) is comprised of 13
exons, with the ATG translational start site located in exon 1 and
the stop codon and polyadenylation signal in exon 13. The gene
spans approximately 68.6 kb and is interrupted by 12 introns, ran-
ging from 68 bp (intron 11) to 28 kb (intron 4) in size (Fig. 1B).
The N-terminal extracellular domain is encoded by four exons,
the transmembrane spanning domains by eight exons, and the
C-terminal tail by one exon.
Multiple transcriptional start sites are located within the
ﬁrst coding exon of Vipr2
The 5¢ untranslated region and transcriptional start site for the
Vipr2 gene were determined by rapid ampliﬁcation of 5¢-cDNA ends
(5¢-RACE) utilising anchored cDNA libraries made from mouse pitu-
itary AtT20 cells and from olfactory bulb tissues isolated from
BALB⁄c and from C57BL⁄6J mice. This also enabled us to determine
if there were additional upstream exons within the gene. Several
cDNA clones from the 5¢-RACE ampliﬁcation of the AtT20 cDNA lib-
rary and from the mouse olfactory bulb cDNA libraries were se-
quenced. The 5¢ ends of all matched the genomic DNA sequence
extending upstream of the translational start site in the ﬁrst coding
exon, the longest AtT20 clone and C57BL⁄6J olfactory bulb clone
Vipr2
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Fig. 1. (A) Schematic diagram of the gene encoding the mouse VPAC2
receptor, Vipr2. The exons encoding the signal peptide sequence (SS),
amino-terminal domain (NT), seven transmembrane domains (TM1-7) and
the carboxyl tail (CT) are indicated underneath. (B) The sequence of the
exon-intron boundaries and the size of each intron.
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Brain
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Kidney
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Lung
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Adrenal gland
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Breast/lactating
Breast/involuting
300 bp
(A)
(B)
Fig. 2. (A) Alignment of sequences derived from different cloned 5¢ RACE products with the Vipr2 exon 1 and 5¢ ﬂanking genomic sequence. The sequences
shown represent the longest products ampliﬁed from each anchored cDNA library, derived from AtT20 D16:16 cells, BALB⁄c and C57BL⁄6J olfactory bulb tis-
sues or the RACE panel shown in (B). The positions of putative Inr elements are indicated by the boxed sequence and the translational start site is indicated
by the dark arrow. The lower case letters indicate intron 1 sequence. (B)5 ¢ RACE analysis of a multitissue RACE panel derived from 24 mouse tissues and
developmental stages. Nested polymerase chain reaction was performed to amplify the 5¢ ends of the mouse VPAC2 receptor as detailed in Materials and
Methods. In the ﬁrst round of ampliﬁcation (20 cycles), an exon 5 speciﬁc Vipr2 primer was used along with the ‘outer’ adapter primer speciﬁc for the anchor
sequence that was included during the cDNA synthesis, followed by a second round of ampliﬁcation (20 cycles) using an exon 3 speciﬁc Vipr2 primer and the
‘inner’ adapter primer. The position of the 300-bp marker is indicated with an arrow.
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a putative Initiator (Inr) element (38) in the genomic DNA sequence
(Fig. 2A). A second Inr-like element is located downstream from this
within exon 1 and ﬂanking the 5¢ end of the longest clone ampli-
ﬁed from the Balb⁄c olfactory bulb library (Fig. 2A).
The possibilities of tissue-speciﬁc and⁄or developmentally regula-
ted alternate 5¢-transcriptional start sites or alternative splicing of
the 5¢ region were also examined by 5¢-RACE. For this, a RACE-
ready panel of anchored cDNA libraries derived from 24 mouse tis-
sues and developmental stages were ampliﬁed with the 5¢-adapter
primer along with a Vipr2 exon 3-speciﬁc oligonucleotide primer, as
detailed in the Materials and Methods. The distance of the exon
3-speciﬁc primer relative to the 5¢ end of the published mouse
cDNA sequence (37) is 289 bp. A single major DNA band of
approximately 300 bp was detected following gel electrophoresis in
eight of the tissues represented in the panel (brain, spleen, stom-
ach, lung, skin, salivary gland and embryonic stages 8–9 days,
9.5 days) (Fig. 2B). These were subcloned and several different cDNA
clones sequenced in order to compare with the previously isolated
cDNA and genomic DNA sequences. All extended 5¢ of the exon 3
speciﬁc primer, matching to varying lengths the original published
mouse cDNA sequence (37) and the AtT20 and olfactory bulb
5¢-RACE cDNA sequences characterised above (Fig. 2A). The longest
clone (SRBrain) was ampliﬁed from the brain and extended 111 bp
upstream of the translational start site, matching genomic DNA
sequence that was ﬂanked by a third putative Inr element upstream
of the ﬁrst one identiﬁed above (Fig. 2A). This strongly suggests
that there is no single transcriptional start site but that transcrip-
tion can start at various points within an 80 bp region at the 5¢
end of exon 1. Several of the various weaker DNA bands were also
subcloned and sequenced, but were found to be either nonspeciﬁc
ampliﬁcation products having the 5¢-adapter primer at both ends
or else matched to varying lengths the sequences determined for
the other 5¢-RACE products (data not shown). None of these exten-
ded further upstream than the SRBrain sequence or contained
additional sequences that would suggest that upstream exons exist
or that the 5¢ end is alternatively spliced. Thus, it seems likely that
the 80 bp region at the 5¢ end of exon 1 constitutes the primary
region responsible for transcription of the Vipr2 gene in mouse.
Functional analysis of the promoter activities in mouse and
rat pituitary cell lines
The sequence of the 5¢ region of Vipr2 was characterised originally
from a 5.6-kb Xba I genomic DNA fragment isolated from the kES-
129 DNA library (Mackay, West, Lutz and Harmar, unpublished data).
This fragment includes the ATG initiation codon (exon 1), 3.2 kb of 5¢
ﬂanking sequence, intron 1, exon 2 and part of intron 2. To evaluate
the promoter activity of the region ﬂanking exon 1, a series of lucif-
erase reporter gene constructs were made by subcloning varying
lengths of the 5¢ 3.2-kb region in front of the luciferase gene in pGL3
Basic. The adjacent 2.2-kb region spanning the translational start site
and part of intron 1 ()32 to +2167) subcloned into pGL3 Basic was
also used. These were transiently expressed in two pituitary clonal cell
lines that endogenously express the VPAC2 receptor, mouse AtT20
D16:16 corticotroph cells and rat GH4C1 somatomammotroph cells,
and in COS 7 cells that do not express this receptor (25). Cells were
cotransfected with the pRL-TK plasmid containing the Renilla lucif-
erase gene under the control of the HSV-thymidine kinase promoter
to normalise results between transfections.
The pGL3-3267 construct containing the region spanning 3300
to )33 relative to the ATG start codon gave high levels of lucif-
erase activity when expressed in AtT20 and GH4C1 cells (Fig. 3),
24.9  3.9- and 155.2  25.4-fold of pGL3 Basic activity, respect-
ively. Low levels of luciferase activity were measured when pGL3-
3267 was expressed in COS 7 cells (2.9  0.1-fold of pGL3 Basic
activity). In comparison, very little luciferase activity was measured
in cells expressing pGL3-2200, which contains the adjacent region
spanning )32 to +2167 (0.06  0.01-, 0.42  0.2- and
0.2  0.02-fold of pGL3 Basic activity, respectively). The pGL3 Con-
trol plasmid containing the SV40 promoter gave 9.1  0.7-,
74.3  34.4- and 66.4  10.2-fold of pGL3 Basic luciferase activity
when expressed in AtT20, GH4C1 and COS 7 cells, respectively. Suc-
cessive 5¢ deletions of the 3.2-kb 5¢ ﬂanking sequence to a 180-bp
region ()212 to )33) maintained high levels of luciferase activity
when expressed in AtT20 and GH4C1 cells (Fig. 3). Deletion of this
180-bp region for the pGL3-3267D180 ()3300⁄)213) abolished lu-
ciferase activity when expressed in all the cell lines used. Taken
together, these results suggest that this 180-bp region forms the
core promoter of the Vipr2 gene.
Identiﬁcation of potential transcription factor binding sites
Analysis of the 3.2-kb 5¢ ﬂanking region using the transcription
factor databases TRANSFAC 3.0 including MatInspector 2.0 (GBF,
Braunschweig, Germany) (39), and TFD (National Institute of Health,
Bethesda, MD, USA) identiﬁed several potential transcription factor
binding sites that may be involved in the tissue- and developmen-
tal-speciﬁc and inducible expression of Vipr2. The 180-bp core pro-
moter region is extremely GC-rich (the GC content is 70%), and
contains in addition to the three Inr-like elements binding sites for
Sp1 and AP2. Within 500 bp of exon 1 are three E-box elements,
including a noncanonical E-box motif for circadian regulation (40)
and two E-box motifs for the NeuroD1⁄Beta2 factor (41) (Fig. 4). In
addition, there are STAT, NF-IL-6 and C⁄EBPb binding sites. Further
upstream are several E-box and GATA elements, a NF-CLEOb site, as
well as sites for YY1, Oct – 1, Brn-2, Isl-1 and C⁄EBPb (Fig. 4).
L1 (LINE-1) polymorphism in the mouse Vipr2 promoter
Lying 705 bp upstream of the translational start site of the mouse
Vipr2 gene, we have discovered a 464-bp DNA sequence that bears
a signiﬁcant similarity to the mouse L1 family, ﬂanked on each end
by a 16-bp terminal repeat sequence. So far, this L1-like element
has been found in the Vipr2 promoter derived from 129 and Balb⁄c
genomic DNA but is not present in the Vipr2 promoter from
C57BL⁄6J (Fig. 4). It contains various putative cis-acting regulatory
elements, including a TATA-box, three CCAAT-boxes and binding
sites for the transcription factors Oct-1 and Brn-2, as well as
E-box, GATA, YY1 and C⁄EBPb sites (Fig. 4), which suggests that
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activity. Conversely, this polymorphism may have a disruptive effect
on the organisation of the promoter’s transcriptional machinery. To
test whether the polymorphism is functionally important, cells were
transfected with luciferase reporter gene constructs containing the
Vipr2 promoter region with or without this sequence. These were
made with the 2.9 kb Balb⁄c( )2892⁄)33) or the 2.4-kb C57BL⁄6J
()2434⁄)33) Vipr2 gene 5¢ ﬂanking sequences, respectively. A sig-
niﬁcant increase in luciferase activity was observed for both repor-
ter constructs when expressed in AtT20 and GH4C1 cells (Fig. 5),
indicating that they are functional promoters. The pGL3-BALB⁄c
construct gave similar levels of luciferase activity as the 129 ge-
nomic DNA construct pGL3-2481 (Fig. 3) when expressed in each of
the cell lines. However, the pGL3-C57BL⁄6J showed three-fold less
activity than pGL3-BALB⁄c when expressed in AtT20 cells, but not
when expressed in GH4C1 cells (Fig. 5). To determine whether this
was cell-speciﬁc, both reporter gene constructs were expressed in
the mouse pituitary aT3-1 gonadotroph cell line, which also expres-
ses the VPAC2 receptor but at low levels (21). The pGL3-C57BL⁄6J
showed three-fold less activity than pGL3-BALB⁄c when expressed
in aT3-1 cells as well, indicating that there may be species- rather
than cell line-differences between the two promoter constructs.
Discussion
In the present study, we have characterised the structure of the
mouse VPAC2 receptor gene, Vipr2, and have identiﬁed the tran-
scriptional start sites and the core promoter region. The relationship
between the intron⁄exon structure of the mouse Vipr2 and the
transmembrane topology that it encodes is highly homologous to
the structure of the human gene (35), and is similar to that repor-
ted for other members of the secretin receptor gene family (42–49).
All of the exon⁄intron boundaries conform to the consensus GT-AG
rule for splice junctions (50). Primer extension was tried in the ﬁrst
instance to determine the transcriptional start site, but was unsuc-
cessful, possibly due to the high GC content and also to there
being multiple sites where transcription can be initiated. Analysis of
the 5¢ UTR of several cDNA clones ampliﬁed from an anchored
AtT20 cDNA library and from anchored olfactory bulb cDNA libraries
from Balb⁄c and C57BL⁄6J mice indicated that transcription can be
initiated at multiple sites. The ﬁrst was identiﬁed from the longest
clone ampliﬁed from the AtT20 library (and corresponding to that
ampliﬁed from the C57BL⁄6J olfactory bulb library) that extended
the 5¢ end of exon 1 to 82 nucleotides upstream of the ATG trans-
lational start site. A second site was identiﬁed within exon 1 from
the longest clone ampliﬁed from the Balb⁄c olfactory bulb cDNA
library that extended 43 nucleotides upstream of the ATG transla-
tional start site. Each is ﬂanked on the 5¢ end by an 8-bp sequence
that resembles an Inr element (pyrimidine, pyrimidine, A(+1), N,
T⁄A, pyrimidine, pyrimidine) (38), with that at the ﬁrst site ()89 to
)82) differing by only one nucleotide. At the end of each of these
Inr-like motifs is the TG dinucleotide, previously deﬁned as one of
the three most preferred initiators by a genome-wide screen (51).
For some members of the secretin receptor gene family, tissue-
and developmentally-speciﬁc alternative promoters and⁄or splicing
of the 5¢ untranslated regions have been reported (52–57). In addi-
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malised to Renilla luciferase activity. Results are shown as fold over pGL3 Basic activity (2.6  0.7 rlu; 0.31  0.22 rlu and 1.1  1.1 rlu for AtT20, GH4C1
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VPAC1 receptor with an altered N-terminal sequence that would
arise from a 5¢-alternatively spliced transcript has been reported in
the database (58), although whether this transcript is functionally
expressed has not yet been determined. The possibility that such
events play a role in the regulation of the Vipr2 gene was examined
here using 5¢-RACE PCR analysis of a panel of anchored cDNA lib-
raries derived from different mouse tissues and developmental sta-
ges. Several cDNAs were sequenced, the longest extending 111 bp
upstream of the ATG translational start site and extending the 5¢
boundary of exon 1. This also was ﬂanked at the 5¢ end by an Inr-
like element located at )120 to )113 in the genomic DNA
sequence, thus identifying a third possible transcriptional start site.
There was no evidence that further exons existed upstream of exon
1 or that the 5¢ end is alternatively spliced, as the 5¢ end of all of
the 5¢-RACE cDNA clones that were sequenced matched that of
exon 1. For two genes that are alternatively spliced in the 5¢-UTR,
the rat PAC1 receptor gene and the mouse PTHR1 gene, a consen-
sus 3¢ splice acceptor site is present a short distance (76 bp and
45 bp, respectively) upstream of the translation start codon (52,
53). No potential splice acceptor sites corresponding to consensus
splice site sequence (3¢ Y11NYAG,G) (59) are found within the cor-
responding region of the mouse Vipr2 gene. Furthermore, we have
determined previously that the 187 bp 5¢-UTR (sequenced from the
longest 5¢-RACE product ampliﬁed from a human placental cDNA
library) and the translational start site of the human gene are
encoded within the same exon (35). Thus, it is likely that exon 1
contains both the major sites for initiation of transcription as well
as for translation for the mouse Vipr2 gene.
The core promoter region for the mouse Vipr2 gene was identi-
ﬁed as a 180 bp sequence located at )212 to )33 relative to the
ATG initiation codon. A CpG island begins 160 bp upstream of the
translational start site and extends 375 bp into intron 1 of Vipr2.
As for the human gene (35), no TATA- or CCAAT-box sequences are
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sensus binding sites for the transcription factor Sp1 and related
factors are present. These, in addition with a broad range of tran-
scriptional start sites, are key features of CpG island promoters (51,
60). Although CpG island promoters are mainly associated with
house-keeping genes, they are also present in the promoter regions
of a signiﬁcant proportion of genes that show tissue-speciﬁc
expression (51, 61). Interestingly, there is increasing evidence that
genes that are active during early development contain CpG island
promoters (62). CpG island promoters may be a common feature
for genes encoding the Group II secretin receptor GPCRs. The pro-
moter regions that have been characterised for the secretin recep-
tor gene family are typically GC-rich, and many have Sp1 sites but
not a TATA-box upstream of the transcriptional start site (45, 48,
52, 57, 63–69). Sp1 sites provide an alternative mechanism to initi-
ate the transcription of genes that do not contain a TATA-box in
their promoter region (70). The Sp1 sites have been shown to be
active for the rat VPAC1 receptor (65), PTH receptor (67), mouse
glucagon receptor (68) and human secretin receptor genes (69).
The mouse and rat Vipr2 promoter regions are highly con-
served, comparison of the 4.5-kb 5¢ region ﬂanking exon 1
between the mouse (C57BL⁄6J) and the rat (accession number
AC096277) genes shows 78% identity. There is much less conser-
vation between the mouse and human (accession number Y18423)
5¢-ﬂanking and exon 1 sequences, the 650-bp regions proximal to
exon 1 have 45% identity between the mouse and human genes.
However, the overall structural features of both promoter regions
are similar. Both have clusters of GATA and E-box sequences as
well as C⁄EBPb binding sites within 3 kb of the translational start
site that may be functionally signiﬁcant for the tissue-speciﬁc
and developmental expression of the gene in human and mouse.
Several E-box sequences that are contained within both promoter
regions are consensus sites for the basic helix-loop-helix factor
NeuroD1⁄Beta2 (41). Within the human VIPR2 promoter, there are
25 NeuroD1⁄Beta2 sites, 24 of which are within the GATA repeat
region (35). C⁄EBPb and NeuroD1⁄Beta2 are important for neuro-
genesis (71, 72) and the development of different pituitary cell
lineages is dependent on both NeuroD1⁄Beta2 and GATA-2 factors
(73). Thus, the presence of these sites within the human and
mouse promoter regions suggests that the VPAC2 receptor may
potentially have a role in these processes in both species. Two
E-box elements within the mouse Vipr2 promoter are binding sites
for the circadian regulators BMAL⁄CLOCK (40, 74) and may be
responsible for the oscillatory modulation of transcription for the
VPAC2 receptor gene in mice (75). The circadian regulator E-box
elements were not found in the corresponding human VIPR2 pro-
moter region.
Lying within the 5¢ ﬂanking sequence of the mouse Vipr2 gene,
we have discovered a 496-bp polymorphic DNA sequence that
bears a signiﬁcant homology to mouse L1 DNA. This sequence is
present in the Vipr2 promoter regions in 129 and BALB⁄c but not
in C57BL⁄6J. L1 elements constitute the most common family of
long interspersed elements in the mammalian genome (76). These
mobile genetic elements form part of the retrotransposon family
and are characterised by the presence of ﬂanking direct repeat
sequences. The self-propagating nature of L1s is due to the pres-
ence of two ORFs, which encode an RNA-binding protein, an
endonuclease, reverse transcriptase and a highly conserved cys-
teine-rich motif, all of which are required for reverse transcription
of the L1 element via an RNA intermediate. Although full length
LINEs are normally approximately 6–7 kb, L1 elements are often
found as inactive truncated versions which are incapable of retro-
transposition (77). The function of L1 elements remains elusive
but it appears that these molecular parasites exist only to main-
tain themselves and their presence in the genome is far from
insigniﬁcant. We have shown here that the L1 sequence within
the promoter region of the Vipr2 gene confers a three-fold
increased level of expression for the luciferase reporter gene con-
struct pGL3-BALB⁄c compared to pGL3-C57BL⁄6J containing the
equivalent region without this sequence when transiently
expressed in two mouse pituitary cell lines. The simplest explan-
ation for this observation is that elements within the L1 sequence
may enhance expression of the gene. However, this appears unli-
kely as the luciferase reporter gene construct pGL3-551, in which
the 5¢ region, including the L1 sequence, was deleted, maintained
similar levels of expression compared to the pGL3-BALB⁄c con-
struct. A more likely explanation is that the region upstream of
the L1 sequence contains a repressor element (or elements) and
that the L1 sequence contains an element that binds a transcrip-
tional regulator that ‘relieves’ this repression. One such candidate
is the multifunctional transcription factor Yin Yang-1 (YY1), which
can act as a transcriptional repressor, activator or initiator,
depending on the context of its binding site in relation to those
of other transcription factors (78). For the Vipr2 gene, a YY1
repressor site is located approximately 1.25 kb upstream of the L1
sequence and a YY1 activator site is located midway within the
L1 sequence. However, there are several elements within the L1
sequence that may contribute to the enhanced level of expression
that is observed and we are currently investigating these to
ascertain which are relevant.
In summary, the exon⁄intron organisation of the mouse VPAC2
receptor gene, Vipr2, is highly conserved with that of the human
gene and with other genes encoding Group II secretin receptor
GPCRs. Transcription of Vipr2 is initiated from multiple sites within
an 80 bp region at the 5¢ end of exon 1 and the core promoter
region is contained within the GC-rich region proximal to the ATG
translational start site. Several regulatory sites located upstream of
the core promoter region were identiﬁed that may contribute to
the tissue-speciﬁc, inducible and developmentally regulated expres-
sion pattern observed for Vipr2 mRNA. In addition, a polymorphic
L1-like sequence was identiﬁed that is present in the Vipr2 promo-
ter regions of 129 and BALB⁄c mice, but not in C57BL⁄6J, that
could potentially contribute to differential expression levels of the
gene. The functional consequences of this remain to be explored.
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